$DSGN
Design Therapeutics, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022003369 Filed on March 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.611M $3.790M $11.05M
YoY Change 154.75% 342.12%
% of Gross Profit
Research & Development $8.759M $7.337M $24.78M
YoY Change 126.04% 308.88%
% of Gross Profit
Depreciation & Amortization $82.00K $82.00K $129.0K
YoY Change 1950.0% 2480.0%
% of Gross Profit
Operating Expenses $13.37M $11.13M $35.83M
YoY Change 135.39% 318.78%
Operating Profit -$13.37M -$35.83M
YoY Change 135.39% 330.14%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $105.0K $62.00K $298.0K
YoY Change -36.75% 496.0%
Pretax Income -$13.27M -$11.07M -$35.53M
YoY Change 140.74% 329.14%
Income Tax
% Of Pretax Income
Net Earnings -$13.27M -$11.07M -$35.53M
YoY Change 140.57% 329.14%
Net Earnings / Revenue
Basic Earnings Per Share -$0.24 -$0.77
Diluted Earnings Per Share -$239.0K -$199.5K -$773.5K
COMMON SHARES
Basic Shares Outstanding 55.70M 55.66M 45.94M
Diluted Shares Outstanding 55.51M 45.94M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $371.2M $384.1M $384.1M
YoY Change -9.75% 964.15% 964.18%
Cash & Equivalents $287.3M $298.6M $298.6M
Short-Term Investments $83.91M $85.50M $85.50M
Other Short-Term Assets $112.0K $7.000K $1.371M
YoY Change -72.0% -72.0% 814.0%
Inventory
Prepaid Expenses $2.439M $1.254M
Receivables
Other Receivables
Total Short-Term Assets $373.9M $385.4M $385.4M
YoY Change -9.2% 963.77% 963.86%
LONG-TERM ASSETS
Property, Plant & Equipment $1.448M $1.508M $5.122M
YoY Change 1348.0% 2023.94% 7217.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $4.930M $5.122M $5.122M
YoY Change 4830.0% 1709.89% 1666.21%
TOTAL ASSETS
Total Short-Term Assets $373.9M $385.4M $385.4M
Total Long-Term Assets $4.930M $5.122M $5.122M
Total Assets $378.8M $390.6M $390.6M
YoY Change -8.03% 969.55% 969.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.901M $1.620M $1.620M
YoY Change -6.49% 15.8% 15.71%
Accrued Expenses $3.579M $3.663M $3.663M
YoY Change 113.93% 293.45% 293.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.480M $5.283M $5.283M
YoY Change 47.87% 126.74% 126.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.012M $3.144M $3.144M
YoY Change 2021.13% 2068.28% 1996.0%
Total Long-Term Liabilities $3.012M $3.144M $3.144M
YoY Change 2021.13% 2068.28% 1996.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.480M $5.283M $5.283M
Total Long-Term Liabilities $3.012M $3.144M $3.144M
Total Liabilities $8.492M $8.427M $8.427M
YoY Change 120.69% 240.48% 239.8%
SHAREHOLDERS EQUITY
Retained Earnings -$60.70M -$47.46M
YoY Change 248.11% 298.02%
Common Stock $432.4M $429.8M
YoY Change 1.62% 94995.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $370.3M $382.1M $382.1M
YoY Change
Total Liabilities & Shareholders Equity $378.8M $390.6M $390.6M
YoY Change -8.03% 969.55% 969.43%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$13.27M -$11.07M -$35.53M
YoY Change 140.57% 329.14%
Depreciation, Depletion And Amortization $82.00K $82.00K $129.0K
YoY Change 1950.0% 2480.0%
Cash From Operating Activities -$11.83M -$9.227M -$29.38M
YoY Change 219.91% 238.87%
INVESTING ACTIVITIES
Capital Expenditures $76.00K -$354.0K $1.538M
YoY Change 130.3% 1923.68%
Acquisitions
YoY Change
Other Investing Activities $490.0K -$49.71M -$52.11M
YoY Change -99.21% 55.59%
Cash From Investing Activities $414.0K -$50.06M -$53.64M
YoY Change -98.2% 59.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 156.0K 193.0K 379.2M
YoY Change -99.96% 751.55%
NET CHANGE
Cash From Operating Activities -11.83M -9.227M -29.38M
Cash From Investing Activities 414.0K -50.06M -53.64M
Cash From Financing Activities 156.0K 193.0K 379.2M
Net Change In Cash -11.26M -59.09M 296.2M
YoY Change -102.83% 12766.64%
FREE CASH FLOW
Cash From Operating Activities -$11.83M -$9.227M -$29.38M
Capital Expenditures $76.00K -$354.0K $1.538M
Free Cash Flow -$11.90M -$8.873M -$30.92M
YoY Change 219.12% 253.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.613497
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001807120
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAsset
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-40288
CY2021 dei Entity Registrant Name
EntityRegistrantName
Design Therapeutics, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3929248
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
6005 Hidden Valley Road
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 110
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92011
CY2021 dei City Area Code
CityAreaCode
858
CY2021 dei Local Phone Number
LocalPhoneNumber
293-4900
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
DSGN
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
480984316
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55700156
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
San Diego, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
298569000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2379000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
85495000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
33712000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1371000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
142000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
385435000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
36233000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1508000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
71000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3614000
CY2020Q4 us-gaap Deferred Costs
DeferredCosts
212000
CY2021Q4 us-gaap Assets
Assets
390557000
CY2020Q4 us-gaap Assets
Assets
36516000
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
20000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1620000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1399000
CY2021Q4 dsgn Accrued Expenses And Other Current Liabilities Related Parties Current
AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent
504000
CY2020Q4 dsgn Accrued Expenses And Other Current Liabilities Related Parties Current
AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent
0
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3663000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
931000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5283000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2330000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3144000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
145000
CY2021Q4 us-gaap Liabilities
Liabilities
8427000
CY2020Q4 us-gaap Liabilities
Liabilities
2475000
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
22012499
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
22012499
CY2021Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
45625000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
45356000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55681752
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16604774
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55441926
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15957821
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
429824000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
451000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47456000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11923000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-244000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
156000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
382130000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-11315000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
390557000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36516000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
226000
CY2021 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
405000
CY2020 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
53000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24778000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6060000
CY2021 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
328000
CY2020 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
292000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11053000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2496000
CY2021 us-gaap Operating Expenses
OperatingExpenses
35831000
CY2020 us-gaap Operating Expenses
OperatingExpenses
8556000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-35831000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-8330000
CY2021 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0
CY2020 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
30000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
298000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
50000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-35533000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8280000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.77
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45936235
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15796674
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-35533000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8280000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-400000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
156000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35933000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8124000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-11315000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
170068000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
254271000
CY2021 dsgn Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
156000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
194000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4689000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-400000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-35533000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
382130000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-3642000
CY2020 dsgn Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
1000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
450000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
156000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8280000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-11315000
CY2021 us-gaap Profit Loss
ProfitLoss
-35533000
CY2020 us-gaap Profit Loss
ProfitLoss
-8280000
CY2021 us-gaap Depreciation
Depreciation
129000
CY2020 us-gaap Depreciation
Depreciation
5000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4689000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29377000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8669000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
86261000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
55589000
CY2021 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
34155000
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
22104000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1538000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
76000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
271000
CY2020 dsgn Conversion Of Stock Amount Converted Related Party
ConversionOfStockAmountConvertedRelatedParty
354000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
24000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
450000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
77000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
71000
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
12000
CY2020 dsgn Paid In Kind Interest Related Party
PaidInKindInterestRelatedParty
26000
CY2021 dsgn Net Change In Operating Lease Right Of Use Assets And Liabilities Related Party
NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty
19000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1017000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
341000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-201000
CY2021 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
2418000
CY2020 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
1430000
CY2021 dsgn Increase Decrease In Accounts Payable And Other Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties
-5000
CY2020 dsgn Increase Decrease In Accounts Payable And Other Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties
-1843000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
144000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-53644000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33561000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
254271000
CY2021 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
124712000
CY2020 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
44731000
CY2021 dsgn Issue Of Common Stock Through Employee Stock Purchase Plan
IssueOfCommonStockThroughEmployeeStockPurchasePlan
194000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
34000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2020 dsgn Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
200000
CY2020 dsgn Repayments Of Notes Payable Related Party
RepaymentsOfNotesPayableRelatedParty
400000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
379211000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44532000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
296190000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2302000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2379000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298569000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2379000
CY2021 dsgn Initial Recognition Of Operating Lease Right Of Use Asset And Operating Lease Liability
InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability
3786000
CY2021 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
5-for-1
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
5
CY2021 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-1.63
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47500000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
384100000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></p>
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 dsgn Short Term Lease Liability
ShortTermLeaseLiability
0
CY2020Q4 dsgn Short Term Lease Liability
ShortTermLeaseLiability
0
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2917434
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15752765
CY2021Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
383609000
CY2020Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
35812000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
85739000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
244000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
85495000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
33556000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
156000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
33712000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
38
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
0
CY2021Q4 dsgn Number Of Domestic Certificates Of Deposit Held
NumberOfDomesticCertificatesOfDepositHeld
24
CY2021Q4 dsgn Accrued Interest Receivable On Available For Sale Investment Securities
AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities
100000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1254000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
60000
CY2020Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
47000
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
110000
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
10000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
7000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
25000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1371000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
142000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1642000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
76000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
134000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1508000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
71000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2152000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
565000
CY2021Q4 dsgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
516000
CY2020Q4 dsgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
266000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
489000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
506000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
100000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3663000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
931000
CY2021Q3 dsgn Lease Agreement Termination Date
LeaseAgreementTerminationDate
2021-09
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
733000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
755000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
778000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
801000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
825000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
561000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4453000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
820000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3633000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
600000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2019Q4 dsgn Unvested Stock Liability
UnvestedStockLiability
1000
CY2020 dsgn Shares Early Exercised Unvested Stock Liability
SharesEarlyExercisedUnvestedStockLiability
145000
CY2020 dsgn Unvested Stock Liability Vested Shares Value
UnvestedStockLiabilityVestedSharesValue
-1000
CY2020Q4 dsgn Unvested Stock Liability
UnvestedStockLiability
145000
CY2021 dsgn Unvested Stock Liability Vested Shares Value
UnvestedStockLiabilityVestedSharesValue
122000
CY2021Q4 dsgn Unvested Stock Liability
UnvestedStockLiability
23000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
30674
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.003
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y11M12D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1723913
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.93
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
153373
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.95
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1601214
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.91
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y8M15D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8468000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1439444
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.60
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
52974
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.65
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
313909
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.82
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2673775
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.49
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
35343000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2673775
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.49
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y1M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
35343000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
949102
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.34
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
800
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M25D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7283
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7293
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0104
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0062
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2836000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1013000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
153000
CY2021Q4 dsgn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
763000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
532000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
25000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y9M10D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
18159000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.39
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.49
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
15.60
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
5.08
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4689000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
450000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
18000000.0
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
CY2021Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2021 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2020 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9171000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
515000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
196000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11994000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3210000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11235000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3177000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
759000
CY2021Q4 dsgn Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
759000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
33000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
759000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
33000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
33000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7451000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1738000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-4000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-552000
CY2020 dsgn Income Tax Reconciliation Debt Financing
IncomeTaxReconciliationDebtFinancing
6000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-836000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-71000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
317000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
174000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7974000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2181000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
402000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
418000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15000
CY2019Q1 us-gaap Convertible Debt
ConvertibleDebt
200000
CY2019Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08
CY2019Q1 dsgn Percentage Of Selling Price Per Share That Can Convertible Into Equity Securities Sold
PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold
0.80
CY2020Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
500000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0

Files In Submission

Name View Source Status
0000950170-22-003369-index-headers.html Edgar Link pending
0000950170-22-003369-index.html Edgar Link pending
0000950170-22-003369.txt Edgar Link pending
0000950170-22-003369-xbrl.zip Edgar Link pending
dsgn-20211231.htm Edgar Link pending
dsgn-20211231.xsd Edgar Link pending
dsgn-20211231_cal.xml Edgar Link unprocessable
dsgn-20211231_def.xml Edgar Link unprocessable
dsgn-20211231_htm.xml Edgar Link completed
dsgn-20211231_lab.xml Edgar Link unprocessable
dsgn-20211231_pre.xml Edgar Link unprocessable
dsgn-ex10_3.htm Edgar Link pending
dsgn-ex23_1.htm Edgar Link pending
dsgn-ex31_1.htm Edgar Link pending
dsgn-ex32_1.htm Edgar Link pending
dsgn-ex4_3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img215454963_0.jpg Edgar Link pending
img215454963_1.jpg Edgar Link pending
img215454963_10.jpg Edgar Link pending
img215454963_11.jpg Edgar Link pending
img215454963_12.jpg Edgar Link pending
img215454963_2.jpg Edgar Link pending
img215454963_3.jpg Edgar Link pending
img215454963_4.jpg Edgar Link pending
img215454963_5.jpg Edgar Link pending
img215454963_6.jpg Edgar Link pending
img215454963_7.jpg Edgar Link pending
img215454963_8.jpg Edgar Link pending
img215454963_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending